Cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is widely used as a chemotherapy combination for the adjuvant treatment of breast cancer. The 'classical' CMF regimen comprises 6 cycles of oral cyclophosphamide (100 mg m -2 day -1 ) days 1-14 with intravenous (i.v.) methotrexate (40 mg m -2 ) and i.v. 5-fluorouracil (600 mg m -2 ) on days 1 and 8, repeated every 28 days (Bonadonna and Valagussa, 1981) . To improve the therapeutic index, the dosages, schedule and route of administration of CMF have been widely varied. Several trials have suggested that relapse-free survival and overall survival not only depend on the total dose of the cytotoxic drugs actually administered, but the more so on the dose intensity, i.e. the amount of drug given per unit of time (Bonadonna and Valagussa, 1981; Hryniuk and Bush, 1984; Hryniuk and Levine, 1986; Hryniuk et al, 1987; Tannock et al, 1988; Ang et al, 1989; Engelsman et al, 1991; Wood et al, 1994) .
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Based on the assumptions that compliance with oral cyclophosphamide would be less than when the drug was given i.v. and that variability in absorption of cyclophosphamide by the oral route could lead to variable bio-availability, several studies have used i.v. CMF schedules. A potential advantage of the i.v. regimens is the easier possibility of a combination with a haematopoietic growth factor such as granulocyte colony-stimulating factor (G-CSF). G-CSF stimulates the recovery of granulocytes after chemotherapy. G-CSF has been used to enhance dose intensity by shortening the interval between cycles or by increase in dosage (Bronchud et al, 1989; Neidhart et al, 1989; Crawford et al, 1991; Lieschke and Burgess, 1992; Biesma et al, 1992; De Graaf et al, 1996; Ribas et al, 1996) .
The aim of the present prospective study was to evaluate the feasibility of a regimen with an intensified i.v. CMF schedule supported by G-CSF and administered every 3 weeks, reaching a projected dose intensity (DI) of 143% compared to 'classical' CMF.
PATIENTS AND METHODS
Eligible were premenopausal women who were considered for adjuvant chemotherapy with CMF. Primary treatment consisted of a modified radical mastectomy or breast-conserving surgery. Patients were ineligible if they had renal impairment (serum creatinine level > 120 µmol l ). Patients received cyclophosphamide 750 mg m -2 , methotrexate 40 mg m -2 and 5-fluorouracil 600 mg m -2 , all i.v. on days 1 and 8, repeated every 21 days, for a total of 6 cycles. The administration of the chemotherapy on days 1 and 8 were defined as two separate courses (A and B), so patients received a total of 12 courses. G-CSF (Neupogen, Roche, Mijdrecht, The Netherlands) was administered in a dose of 300 µg subcutaneously once a day on days 9-18 of each cycle. Blood counts were collected on days 1 and 8 before i.v. administration of the chemotherapeutic drugs. The chemotherapy was administered if the leucocyte count was > 2.5 × 10 9 l -1 on day 1 or > 1.0 × 10 9 l -1 on day 8 and if the platelet count was > 75 × 10 9 l -1 on day 1 and > 50 × 10 9 l -1 on day 8. These non-conventional thresholds, which were allowed by the support Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer of G-CSF, were applied to minimize the delay of treatment due to myelosuppression and to achieve a dose-intensive CMF regimen. In the event of myelosuppression on the planned day of drug administration, treatment was delayed for 1 week. No dose reductions were scheduled for nadir values or intercurrent fever. Red blood cell transfusion was administered for haemoglobin values < 6.5 mmol l -1 . Radiation therapy was administered in case of involvement of more than three positive lymph nodes, extranodal tumour growth, multifocal tumour or breast lymphangitis. Radiotherapy was administered concomitantly with CMF chemotherapy.
Toxicity was recorded using the WHO criteria (WHO, 1979) . The total dose of the chemotherapeutic drugs was expressed as the percentage of the actual amount administered divided by the projected amount, in which each drug was given equal value. The DI was given as a percentage of the total dose administered per unit time (weeks), divided by the actual duration of treatment. The study was approved by the Medical Ethical Committee and all patients gave informed consent.
The χ 2 test (Mantel-Haenszel) was used for statistical analysis with the exception of the analysis of the leucocyte counts related to Figure 1 . For this purpose Friedman's test (two-way rank analysis) was used together with Duncan's test for correction of multiple comparisons. The confidence intervals were 95%.
RESULTS

Patient characteristics
Over a period of 1 year, 23 women entered the study. Twenty-one patients had undergone a modified radical mastectomy and two patients breast-conserving surgery. Twenty-two patients had lymph node involvement, two had more than four positive nodes, one patient was node-negative. Six patients received loco-regional radiation therapy, including two with breast conserving therapy. The median start of the chemotherapy was 19 days (range 14-48) and of radiotherapy 64 days after surgery (range 43-78 days). The patients' characteristics are shown in Table 1 .
Dose intensity
Two patients did not receive all courses of chemotherapy. One patient had fever with leukopenia and skipped course 4B. Another patient did not receive the last course (6B) due to haematological toxicity. A total of 274 out of 276 courses were completed. Table 2 shows the actually achieved DI as a percentage of the projected DI (range 78-100%) and the actually achieved DI compared to 'classical' CMF (range 111-143%). In 21 patients the actually delivered DI was ≥ 85% of the projected DI, which is the equivalent of ≥ 120% compared to 'classical' CMF.
Delay of treatment
Out of these 23 patients, ten received all treatment as planned; delay of treatment occurred in 13 patients (57%). A total of 17 courses out of 274 (6.2%) were delayed for a median of 1 week (range 1-3 weeks). The total delay was 23 weeks (5.6%) on a projected total treatment duration of 414 weeks for all patients. The reasons for delay of chemotherapy are listed in Table 3 . Delay for insufficient marrow recovery and for fever and infection were the most important causes. Figure 1 shows the median leucocyte count with ranges at the start of the courses. Over time, the median leucocyte count on day 8 declined, suggesting cumulative toxicity. Moreover, the absolute increase of leucocytes during G-CSF administration (i.e. the reserve-capacity) declined. The relative increase of leucocytes related to the nadir in these cycles, however, were not different. Overall, these changes indicate a gradual fall in bone marrow reserve capacity. Thirteen out of 23 patients (57%) were at least once (range 1-3) affected by fever grade 2 (temperature > 38.0°C) and were treated by oral or i.v. antibiotics. Eleven patients (48%) were treated by oral antibiotics (infection grade 2). Four out of 23 patients (17%) had fever with neutropenia and were admitted for i.v. antibiotics (infection grade 3). The time to the first episode of infection is shown in Figure 2 . One prophylactic transfusion of platelets was given for grade IV thrombocytopenia without bleeding. Red blood cell (RBC) transfusions were administered to 12 patients (52%) at a median value of haemoglobin of 5.5 mmol l -1 . The median number of transfusions was 3 units (range 2-6), for a total of 45 units. Figure 3 shows the cumulative probability of the first RBC transfusion during treatment.
Toxicity
The main toxicity related to the use of G-CSF was mild bone pain in seven patients (mainly in the first two cycles during the last days of G-CSF) and musculoskeletal pain in two patients and was not a reason to withhold its administration.
Radiotherapy
Six patients received radiation therapy. All six patients received the projected total dose. The actual achieved DI was for three patients 100%, for two patients 95% and for one patient 90%. Insufficient leucocyte recovery (leucocyte count ≤ 3 × 10 9 l -1 ) occurred in 23 of 72 courses (32%) versus in 64 of 204 courses (32%) without radiotherapy (ns). One patient treated with radiotherapy was hospitalized for infection grade 3 and RBC transfusion was administered to three patients (ns).
DISCUSSION
We have studied the feasibility of an accelerated CMF schedule aiming to reach a higher dose intensity. The dose-intensification was achieved by shortening the cycle interval and by slightly increasing the dose of cyclophosphamide, supported by G-CSF. The dose intensity for cyclophosphamide was 500 mg m -2 week -1 i.v., a factor 1.43 compared to the 'classical' CMF regimen (350 mg m -2 week -1 orally). The dose intensity for methotrexate and 5-fluorouracil was 133% compared to the oral schedule. With this modified schedule, the median actually achieved dose intensity was 135% compared to the 'classical' CMF. Recently, Goldhirsch et al concluded that the many variations in CMF regimens did not improve results (Goldhirsch et al, 1998a (Goldhirsch et al, , 1998b . However, several studies have suggested that a higher dose or dose intensity of chemotherapy may improve disease-free and overall survival (Bonadonna and Valagussa, 1981; Hryniuk and Bush, 1984; Hryniuk and Levine, 1986; Hryniuk et al, 1987; Tannock et al, 1988; Ang et al, 1989; Engelsman et al, 1991; Wood et al, 1994) . Bonadonna and Valagussa (1981) suggested after a retrospective analysis, that the effectiveness of adjuvant CMF depends on the total dose actually administered. CMF was only useful when given ≥ 85% of the planned dose (Bonadonna and Valagussa, 1981) . Wood et al reported the results of a prospective, randomized trial of adjuvant cyclophosphamide, doxorubicin and 5-fluorouracil in three dose levels (Wood et al, 1994) . The women treated with a moderate or high dose intensity had a significantly longer disease-free and overall survival than those treated with a low dose intensity. Tannock et al reported a reduction in response rate and overall survival in patients who received the lower (50%) dose arm compared to the standard intravenous CMF in metastatic disease (Tannock et al, 1988 ).
An advantage of giving cyclophosphamide i.v. is the possibility to start G-CSF immediately after the second i.v. dose from day 8 onwards and thus shorten the interval between the cycles. Several studies examining the route of administration have been published (Engelsman et al, 1991; Lindeman et al, 1992 ). An EORTC randomized study has compared 'classical' CMF with i.v. CMF (cyclophosphamide 600 mg m , all i.v. on day 1) in 254 eligible patients with metastatic breast cancer (Engelsman et al, 1991) . The response rate after 'classical' CMF was 48% compared with 29% for i.v. CMF, but in the 'classical' CMF a higher dose intensity was achieved.
In the present trial the criteria for delay of courses due to myelosuppression were less restricted than in most adjuvant breast cancer protocols, which was allowed by the support of G-CSF. In the hypothetical case that the criteria would have been chosen more stringent (e.g. leucocyte count > 3.0 × 10 9 l -1 and platelet count > 100 × 10 9 l -1 on day 1 and leucocyte count > 2.0 × 10 9 l -1 and platelet count > 75 × 10 9 l -1 on day 8), course A would have been postponed 16 instead of 5 weeks (11.6% vs 3.6%) and course B 41 weeks instead of once (29.7% vs 0.7%). This would have resulted in 19 patients (83%) with delay of treatment and an estimated achieved DI of 84% at most. The effect of G-CSF on DI of standard oral adjuvant CMF in 123 patients with breast cancer was studied by De Graaf et al. Without G-CSF the leucocyte count on day one was ≤ 3 × 10 9 l -1 in 21% of the courses (De Graaf et al, 1996) . In our study, the leucocyte count was ≤ 3 × 10 9 l -1 in 32% of the courses. Besides, 17% of the patients had to be treated with i.v. antibiotics and 52% of the patients needed RBC transfusions. With the 'classical' CMF regimen RBC transfusions are rarely given.
G-CSF was administered on days 9-18 and was not given simultaneously with chemotherapy to avoid enhanced myelotoxicity (ASCO, 1994) . Recently, Tjan-Heijnen et al reported that, in small-cell lung carcinoma patients, stopping G-CSF administration 48 h before the next chemotherapy course increased chemotherapy-associated leucopenia and thrombocytopenia, implying a carry-over effect in the next cycles (Tjan-Heijnen et al, 1998) . It might be that stopping G-CSF earlier would yield better results.
Several investigators showed that radiotherapy could have a negative effect on marrow recovery and on the dose intensity in combination with chemotherapy (Holland et al, 1980; Cooper et al, 1981; Levine et al, 1984; De Graaf et al, 1996) . This was especially seen when G-CSF was administered in conjunction with the radiotherapy, leading to additional delays for thrombocytopenia. However, Pronzato et al did not find a negative effect of radiotherapy on the dose intensity of adjuvant CMF (Pronzato et al, 1993) . In our study, the subgroup of patients having received radiation therapy had equal dose intensity and there was no difference in infection rate. We can not therefore in this small group confirm an adverse impact of radiotherapy.
We conclude that this modified i.v. CMF regimen carries enhanced haematological toxicity with clinical sequelae (namely fever, i.v. antibiotics and many RBC transfusions), but allows a high dose intensity in a majority of patients. This dose-intensive CMF schedule could be the basis for a randomized phase III study to compare with 'classical' CMF. Such a study should also examine dose-intensity, toxicity, cost and quality of life. It should be possible to use erythopoietin for treatment of anaemia and prophylactic antibiotics to prevent infections. Also, repeated peripheral stem cell support could be used to achieve high dose intensity with less haematological toxicity.
